Abstract
Objective
To evaluate the role of 68Ga-labelled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-NaI3-Octreotide (68Ga-DOTA-NOC) whole body positron emission tomography-computed tomography (PET-CT) as a functional imaging approach for phaeochromocytoma and paraganglioma.
Methods
Thirty-five unrelated patients (Median age-34.4 years; range: 15–71) were evaluated in this prospective study. PET-CT was performed after injection of 132–222 MBq of 68Ga-DOTA-NOC. Images were evaluated by two experienced nuclear medicine physicians both qualitatively as well as quantitatively (standardised uptake value-SUVmax). In addition we compared the findings with 131I Metaiodobenzylguanidine (MIBG) scintigraphy, which was available for 25 patients. Histopathology and/or conventional imaging with biochemical markers were taken as the reference standard.
Results
44 lesions were detected on 68Ga-DOTA-NOC PET-CT imaging with an additional detection of 12 lesions not previously known, leading to a change in management of 6 patients. Sensitivity, specificity and accuracy were 100%, 85.7%, and 97.1% on a per patient basis and 100%, 85.7% and 98% on per lesion basis, respectively.131I MIBG scintigraphy was concordant with 68Ga-DOTA-NOC PET-CT in 16 patients and false negative in 9 patients.
Conclusion
68Ga-DOTA-NOC PET-CT is highly sensitive and specific for the detection of phaeochromoctyomas and paragangliomas. It seems better than 131I MIBG scintigraphy for this purpose.
Key Points
• 68 Ga-DOTA-NOC PET-CT seems useful in patients with phaeochromocytoma and paraganglioma.
• This prospective single centre study showed that it has high diagnostic accuracy.
• 68 Ga-DOTA-NOC PET-CT seems superior to 131 I-MIBG in these patients.
Similar content being viewed by others
References
Gifford RW Jr, Manger WM, Bravo EL (1994) Pheochromocytoma. Endocrinol Metab Clin North Am 23:387–404
Werbel SS, Ober KP (1995) Pheochromocytoma: update on diagnosis, localization, and management. Med Clin North Am 79:131–153
Manger WM, Gifford RW (1995) Pheochromocytoma: a clinical overview. In: Laragh JH, Brenner BM (eds) Hypertension: pathophysiology, diagnosis and management. Raven, New York, pp 225–244
Neumann HPH, Berger DP, Sigmund G et al (1993) Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel- Lindau disease. N Engl J Med 329:1531–1538
Moreira SG Jr, Pow-Sang JM (2002) Evaluation and management of adrenal masses. Cancer Control 9:326–334
Bravo EL (1994) Evolving concepts in the pathophysiology, diagnosis and treatment of pheochromocytoma. Endocr Rev 15:356–368
CapellaC RivaC, Cornaggia M et al (1988) Histopathology, cytology and cytochemistry of pheochromocytomas and paragangliomas including chemodectomas. Path Res Pract 183:176–187
Grufferman S, Gillman MW, Pasternak LR et al (1980) Familial carotid body tumors: case report and epidemiologic review. Cancer 46:2116–2122
Kliewer KE, Wen DR, Cancilla PA et al (1989) Paragangliomas: assessment of prognosis by histologic, immunohistochemical, and ultrastructural techniques. Hum Pathol 20:29–39
Lack EE, Cubilla AL, Woodruff JM (1979) Paragangliomas of the head and neck region. A pathologic study of tumors from 71 patients. Hum Pathol 10:191–218
Kudva YC, Sawka AM, Young WF Jr (2003) Clinical review 164: the laboratory diagnosis of adrenal pheochromocytoma—the Mayo Clinic experience. J Clin Endocrinol Metab 88:4533–4539
Neumann HPH, Bender BU, Reincke M et al (1999) Adrenal sparing surgery for pheochromocytoma. Br J Surg 84:94–97
Quint LE, Glazer GM, Francis IR et al (1987) Pheochromocytoma and paraganglioma: comparison of MRI imaging with CT and 131I MIBG scintigraphy. Radiology 165:89–93
Connor CS, Hermreck AS, Thomas JH (1988) Pitfalls in the diagnosis of pheochromocytoma. Am Surg 54:634–636
Khafagi FA, Shapiro B, Fig LM et al (1989) Labetalol reduces 131I MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 30:481–489
Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20:157–198
Jochen M, Nicole U, Stefan S et al (2003) Somatostatin Receptor Subtypes in Human Pheochromocytoma: Subcellular Expression Pattern and Functional Relevance for Octreotide Scintigraphy. J Clin Endocrinol Metab 88:5150–5157
Van der Harst E, De Herder WW, Bruining HA et al (2000) 123[I] Metaiodobenzylguanidine and 111[In] octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86:685–693
Zhernosekov KP, Filosofov DV, Baum RP et al (2007) Processing of Generator-Produced 68Ga for Medical Application. J Nucl Med 48:1741–1748
Eriksson B, Orlefors H, Oberg K et al (2005) Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 19:311–324
Taïeb D, Sebag F, Barlier A et al (2009) 18F-FDG Avidity of Pheochromocytomas and Paragangliomas: A New Molecular Imaging Signature? J Nucl Med 50:711–717
Shuklin BL, Thompson NW, Shapiro B et al (1999) Pheochromocytomas: Imaging with 2-[Fluorine-18] fluoro-2-deoxy-D-glucose PET. Radiology 212:35–41
Trampal C, Engler H, Juhlin C et al (2004) Pheochromocytomas: Detection with 11C Hydroxyephedrine PET. Radiology 230:423–428
Hoegerle S, Nitzsche E, Altehoefer C et al (2002) Pheochromocytomas: Detection with 18F DOPA Whole-Body PET—Initial Results. Radiology 222:507–512
Ambrosini V, Campana D, Bodei L et al (2010) 68Ga-DOTA-NOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. J Nucl Med 51:669–673
Maecke HR, Hofmann M, Haberkorn U (2005) 68Ga-Labeled Peptides in Tumor Imaging. J Nucl Med 46:172S–178S
Win Z, Al-Nahhas A, Towey D et al (2007) 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun 28:359–363
Mantero F, Massimo T, Arnoldi G et al (2000) A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab 85:637–644
Ueberberg B, Tourne H, Redman A et al (2005) Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland. Horm Metab Res 37:722–728
van der Harst HE, de Herder WW, Bruining HA et al (2001) (123)I metaiodobenzylguanidine and (111)In octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86:685–693
Kaltsas G, Korbonits M, Heintz E et al (2001) Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86:895–902
Kölby L, Bernhardt P, Johanson V et al (2006) Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas? Ann N Y Acad Sci 1073:491–497
Timmers H, Gimenez-Roqueplo AP, Mannelli M, Pacak K (2009) Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer 16:391–400
Burnichon N, Rohmer V, Amar L et al (2009) The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 94:2817–2827
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Naswa, N., Sharma, P., Nazar, A.H. et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study. Eur Radiol 22, 710–719 (2012). https://doi.org/10.1007/s00330-011-2289-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-011-2289-x